<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2025-29-2-27-35</article-id><article-id custom-type="edn" pub-id-type="custom">FSBCHA</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-2416</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Взаимосвязь циркулирующих цитокинов и показателей липидного спектра крови с функциональными параметрами почек у лиц с различным сердечно-сосудистым риском</article-title><trans-title-group xml:lang="en"><trans-title>Relationship of circulation cytokines and blood lipid spectrum with renal functional parameters in persons with various cardiovascular risk</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8513-9279</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Муркамилов</surname><given-names>И. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Murkamilov</surname><given-names>I. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доц. Муркамилов Илхом Торобекович - д-р мед. наук. Кафедра факультетской терапии КГМА им. И.К. Ахунбаева; кафедра терапии №2 КРСУ им. Б.Н. Ельцина.</p><p>720020, г. Бишкек, ул. Ахунбаева, д. 92Тел.: (+996) 557221983</p></bio><bio xml:lang="en"><p>Ilkhom T. Murkamilov - MD, PhD, DMedSci. Department of Faculty Therapy, KSMA named after. I.K. Akhunbaev; DMedSci. Department of Therapy No. 2 KRSU named after. B.N. Yeltsin</p><p>720020, Bishkek, st. Akhunbayev 92, tel. (+996) 557221983</p></bio><email xlink:type="simple">murkamilov.i@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2682-4417</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фомин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fomin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Фомин Виктор Викторович - д-р мед. наук, чл.-кор. РАН Зав. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского, проректор по инновационной и клинической деятельности, ФГАОУ ВО Первый МГМУ имени И.М. Сеченова Минздрава России (Сеченовский Университет)</p><p>119991, Москва, ул. Большая Пироговская, д. 2., Тел.: (495) 609-14-00, доб. 2142</p></bio><bio xml:lang="en"><p>Viktor V. Fomin - MD, PhD, DMedSci. Corresponding Member. RAS, head. cafe Faculty Therapy No. 1 of the Institute of Clinical Medicine. N.V. Sklifosovsky, Vice-Rector for Innovation and Clinical Activities, First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of Russia (Sechenov University)</p><p>2142, 119991, Moscow, st. Bolshaya Pirogovskaya, 2, tel. (495) 609-14-00</p></bio><email xlink:type="simple">fomin_vic@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8387-5800</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сабиров</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sabirov</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>терапии № 2 медицинского факультета КРСУ им. Б.Н. Ельцина.</p><p>720022, г. Бишкек, ул. Киевская, д. 44. Тел.: (996) 555 816-842</p></bio><bio xml:lang="en"><p>Ibragim S. Sabirov - MD, PhD, DMedSci. Department of Therapy No. 2 of the Medical Faculty of the KRSU named after. B.N. Yeltsin.</p><p>720022, Bishkek, st. Kyiv, 44, tel. (996) 555 816-842</p></bio><email xlink:type="simple">sabirov_is@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0632-6653</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юсупов</surname><given-names>Ф. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yusupov</surname><given-names>F. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Юсупов Фуркат Абдулахатович - д-р мед. наук Зав. каф. неврологии, нейрохирургии и психиатрии медицинского факультета ОшГУ, член правления Общества специалистов по хронической болезни почек Кыргызстана, главный невролог Южного региона Кыргызстана.</p><p>714000, Кыргызстан, г. Ош, ул. Ленина, д. 331. Тел.: (+996) 557202071</p></bio><bio xml:lang="en"><p>Furkat A. Yusupov - MD, PhD, DMedSci. Head. cafe Neurology, Neurosurgery and Psychiatry of the Medical Faculty of Osh State University, Member of the Board of the Society of Specialists in Chronic Kidney Disease of Kyrgyzstan, Chief Neurologist of the Southern Region of Kyrgyzstan.</p><p>714000, Osh, st. Lenina 331, tel. (+996) 557202071</p></bio><email xlink:type="simple">furcat_y@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2323-5702</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Айдаров</surname><given-names>З. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Aidarov</surname><given-names>Z. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Айдаров Зиябидин Абдирайимович - д-р мед. наук Декан факультета «Лечебное дело» КГМА им. И.К. Ахунбаева, член правления Общества специалистов по хронической болезни почек Кыргызстана.</p><p>720020, Бишкек, ул. Ахунбаева, д. 92</p></bio><bio xml:lang="en"><p>Ziyabidin A. Aidarov. MD, PhD, DMedSci. Dean of the Faculty of General Medicine, KSMA named after I.K. Akhunbaev, Member of the Board of the Society of Specialists in Chronic Kidney Disease of Kyrgyzstan.</p><p>720020, Bishkek, st. Akhunbaev 92</p></bio><email xlink:type="simple">k_i_o2403@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3007-8127</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кудайбергенова</surname><given-names>И. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Kudaibergenova</surname><given-names>I. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Кудайбергенова Индира Орозобаевна - д-р мед. наук Ректор КГМА им. И.К. Ахунбаева.</p><p>Кыргызстан, 720020, г. Бишкек, ул. Ахунбаева, д. 92</p></bio><bio xml:lang="en"><p>Indira O. Kudaibergenova - MD, PhD, DMedSci, rector of KSMA named after I.K. Akhunbaev.</p><p>720020, Bishkek, st. Akhunbaev 92</p></bio><email xlink:type="simple">k_i_o2403@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кыргызская государственная медицинская академия им. И.К. Ахунбаева; Кыргызско-Российский Славянский университет им. первого Президента РФ Б.Н. Ельцина</institution><country>Кыргызстан</country></aff><aff xml:lang="en"><institution>Kyrgyz State Medical Academy named after I.K. Akhunbaev; Kyrgyz-Russian Slavic University named after the First President of the Russian Federation B.N. Yeltsin</institution><country>Kyrgyzstan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSAEI HE First Moscow State Medical University named after I.M. Sechenov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Кыргызско-Российский Славянский университет им. первого Президента РФ Б.Н. Ельцина</institution><country>Кыргызстан</country></aff><aff xml:lang="en"><institution>Kyrgyz-Russian Slavic University named after the First President of the Russian Federation B.N. Yeltsin</institution><country>Kyrgyzstan</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Ошский государственный университет</institution><country>Кыргызстан</country></aff><aff xml:lang="en"><institution>Osh State University</institution><country>Kyrgyzstan</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Кыргызская государственная медицинская академия им. И.К. Ахунбаева</institution><country>Кыргызстан</country></aff><aff xml:lang="en"><institution>Kyrgyz State Medical Academy named after I.K. Akhunbaev</institution><country>Kyrgyzstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>04</day><month>06</month><year>2025</year></pub-date><volume>29</volume><issue>2</issue><fpage>27</fpage><lpage>35</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Муркамилов И.Т., Фомин В.В., Сабиров И.С., Юсупов Ф.А., Айдаров З.А., Кудайбергенова И.О., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Муркамилов И.Т., Фомин В.В., Сабиров И.С., Юсупов Ф.А., Айдаров З.А., Кудайбергенова И.О.</copyright-holder><copyright-holder xml:lang="en">Murkamilov I.T., Fomin V.V., Sabirov I.S., Yusupov F.A., Aidarov Z.A., Kudaibergenova I.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/2416">https://journal.nephrolog.ru/jour/article/view/2416</self-uri><abstract><p>ЦЕЛЬ ИССЛЕДОВАНИЯ – изучить взаимосвязь циркулирующих цитокинов с показателями липидного спектра крови и их роль в развитии дисфункции почек у лиц с различными категориями сердечно-сосудистого риска.</p><sec><title>ПАЦИЕНТЫ И МЕТОДЫ</title><p>ПАЦИЕНТЫ И МЕТОДЫ. Обследованы 249 человек с различными категориями сердечно-сосудистого риска (ССР) по шкале SCORE: низкоумеренный ССР (n = 92), высокий ССР (n = 100), очень высокий (n = 57). Наряду с общеклиническими данными, оценивались следующие биохимические параметры: концентрации фактора некроза опухоли-альфа (ФНО-α), интерлейкина (ИЛ)-6 и ИЛ-10, соотношение воспалительных и противовоспалительных цитокинов, а также уровни содержания общего холестерина (ХС), ХС липопротеинов низкой плотности (ХС-ЛПНП), триглицеридов (ТГ), ХС липопротеинов высокой плотности (ХС-ЛПВП), индекс атерогенности (ИА), сывороточного цистатина С и креатинина с расчетом скорости клубочковой фильтрации (СКФ).</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Полученные результаты исследования показывают, что у лиц с очень высоким ССР уровень систолического артериального давления, медиана концентрации ИЛ-6 и ИЛ-10 были значимо выше. Расчетная СКФ по уровню сывороточного цистатина С во всех изучаемых подгруппах оказалась существенно ниже по сравнению СКФ, вычисленной по креатинину крови. Продемонстрирована тесная корреляция между концентрацией ФНО-α с уровнем ХС-ЛПНП (r = 0,138, p&lt;0,05), ХС-ЛПВП (r = -0,193, p&lt;0,05), ИА (r = 0,140, p&lt;0,05), с одной стороны, и между ИЛ-6 с ХС-ЛПНП (r = 0,253, p&lt;0,05), ХС-ЛПВП (r = -0,174, p&lt;0,05) – с другой. Отмечалась отрицательная взаимосвязь между уровнем ФНО-α со СКФ, рассчитанной как по креатинину (r = -0,270, p&lt;0,05), так и по цистатину С (r = -0,308, p&lt;0,05).</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Наиболее выраженные нарушения цитокинового обмена с повышением ФНО-α, ИЛ-6 и снижением ИЛ-10 отмечаются по мере нарастания ССР, особенно у лиц с очень высоким ССР. У лиц с различными категориями ССР повышенные уровни ФНО-α и ИЛ-6 активно вовлекаются в нарушение метаболизма липидов, способствуя прогрессированию атеросклероза и развитию дисфункции почек.</p></sec></abstract><trans-abstract xml:lang="en"><p>THE AIM of the study was to study the relationship between circulating cytokines and blood lipid profiles and their role in the development of kidney dysfunction in individuals with different categories of cardiovascular risk. We examined 249 people with different categories of cardiovascular risk (CVR) according to the SCORE scale: low-moderate cardiovascular risk (n = 92); high CV risk (n = 100); very high (n = 57). Along with general clinical data, the following biochemical parameters were assessed: concentrations of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6 and IL-10, the ratio of inflammatory and anti-inflammatory cytokines, as well as the levels of total cholesterol (CHC), lipoprotein cholesterol low density (LDL-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), atherogenic index (AI), serum cystatin C and creatinine with calculation of glomerular filtration rate (GFR).</p><sec><title>PATIENTS AND METHODS</title><p>PATIENTS AND METHODS. Show that in individuals with very high cardiovascular risk, the level of systolic blood pressure, the median concentrations of IL-6 and IL-10 were significantly higher. Estimated GFR based on serum cystatin C levels in all studied subgroups was significantly lower than GFR calculated based on blood creatinine. RESULTS. A close correlation was demonstrated between the concentration of TNF-α with the level of LDL-C (r = 0.138, p&lt;0.05), HDL-C (r = – 0.193, p&lt;0.05), AI (r = 0.140, p&lt;0.05) on the one hand and between IL-6 with LDL-C (r = 0.253, p&lt;0.05), HDL-C (r = -0.174, p&lt;0.05) on the other. There was a negative relationship between the level of TNF-α and GFR calculated from both creatinine (r= -0.270, p&lt;0.05) and cystatin C (r= -0.308, p&lt;0.05).</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. The most pronounced violations of cytokine metabolism with an increase in TNF-α, IL-6 and a decrease in IL-10 are observed as the CVR increases, especially in people with very high CVR. In individuals with different categories of CV risk, elevated levels of TNF-α and IL-6 are actively involved in lipid metabolism disorders, contributing to the progression of atherosclerosis and the development of kidney dysfunction.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>цитокины</kwd><kwd>ФНО-α</kwd><kwd>ИЛ-6</kwd><kwd>липидный спектр</kwd><kwd>функция почек</kwd><kwd>сердечно-сосудистый риск</kwd><kwd>прогноз</kwd><kwd>здравоохранение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cytokines</kwd><kwd>TNF-α</kwd><kwd>IL-6</kwd><kwd>lipid spectrum</kwd><kwd>kidney function</kwd><kwd>cardiovascular risk</kwd><kwd>prognosis</kwd><kwd>healthcare</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Халтурина ЕО, Миронов АЮ. Особенности профиля сывороточных цитокинов у иммунокомпрометированных пациентов с атипичными хроническими активными герпесвирусными инфекциями. Клиническая лабораторная диагностика 2023;68(2):88–94. doi:10.51620/0869-2084-2023-68-2-88-94</mixed-citation><mixed-citation xml:lang="en">Khalturina EO, Mironov AYu. Features of serum cytokines profile in immunocomposed patients with atypical chronic active herpesvirus infections. Klinicheskaya Laboratornaya Diagnostika 2023; 68(2):88–94. (In Russ). doi: 10.51620/0869-2084-2023-68-2-88-94</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">MacCannell A, Straw S, Levelt E. Role of adipose tissue remodeling in diabetic heart disease. Visceral and Ectopic Fat. Elsevier 2023;217–227. doi: 10.1016/B978-0-12-822186-0.00004-3</mixed-citation><mixed-citation xml:lang="en">MacCannell A, Straw S, Levelt E. Role of adipose tissue remodeling in diabetic heart disease. Visceral and Ectopic Fat. Elsevier 2023;217–227. doi: 10.1016/B978-0-12-822186-0.00004-3</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pouresmaeil V, Al Abudi AH, Mahimid AH et al. Evaluation of serum selenium and copper levels with inflammatory cytokines and indices of oxidative stress in Type 2 diabetes. Biological Trace Element Research 2023; 201(2):617–626. doi: 10.1007/s12011022-03191-w</mixed-citation><mixed-citation xml:lang="en">Pouresmaeil V, Al Abudi AH, Mahimid AH et al. Evaluation of serum selenium and copper levels with inflammatory cytokines and indices of oxidative stress in Type 2 diabetes. Biological Trace Element Research 2023; 201(2):617–626. doi: 10.1007/s12011022-03191-w</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Титов ВН. Основы первичной профилактики атеросклероза. Клиническая медицина 2014;92(12):19–29</mixed-citation><mixed-citation xml:lang="en">Titov VN. Fundamentals of primary prevention of atherosclerosis. Klinicheskaya meditsina 2014;92 (12):19–29. (In Russ)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Попкова ТВ, Новикова ДС, Насонов ЕЛ. Ингибирование интерлейкина-6 и сердечно-сосудистая патология у больных ревматоидным артритом. Терапевтический архив 2016;88(5):93–101 doi: 10.17116/terarkh201688593-101</mixed-citation><mixed-citation xml:lang="en">Popkova TV, Novikova DS, Nasonov EL. Interleukin-6 inhibition and cardiovascular disease in patients with rheumatoid arthritis. Terapevticheskiy Arkhiv 2016;88(5):93–101. (In Russ) doi: 10.17116/terarkh201688593-101</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wybranska I. Genetic Markers of Endothelial Dysfunction. Endothelial Dysfunction-A Novel Paradigm. Intech Open 2023. (In Russ). doi: 10.5772/intechopen.109272</mixed-citation><mixed-citation xml:lang="en">Wybranska I. Genetic Markers of Endothelial Dysfunction. Endothelial Dysfunction-A Novel Paradigm. Intech Open 2023. (In Russ). doi: 10.5772/intechopen.109272</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Захарьян ЕА, Агеева ЕС, Шрамко ЮИ и др. Современные представления о диагностической роли биомаркеров эндотелиальной дисфункции и возможностях ее коррекции. Комплексные проблемы сердечно-сосудистых заболеваний 2022;11(4S):194–207. doi: 10.17802/2306-1278-2022-11-4S-194-207</mixed-citation><mixed-citation xml:lang="en">Zakharyan EA, Ageeva ES, Shramko YuI et al. A modern view on the diagnostic role of endothelial dysfunction biomarkers and the possibilities of its correction. Kompleksnye problemy serdechno-sosudistykh zabolevaniy 2022; 11(4S):194–207. (In Russ). doi: 10.17802/2306-1278-2022-11-4S-194-207. (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Surma S, Lewek J, Banach M. Acute Coronary Syndrome: Destabilization of Atherosclerotic Plaque in COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, and Treatment). Cardiovascular Complications of COVID-19: Acute and Long-Term Impacts. – Cham: Springer. International Publishing 2023;121–150. doi: 10.3390/diagnostics13030478</mixed-citation><mixed-citation xml:lang="en">Surma S, Lewek J, Banach M. Acute Coronary Syndrome: Destabilization of Atherosclerotic Plaque in COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, and Treatment). Cardiovascular Complications of COVID-19: Acute and Long-Term Impacts. – Cham: Springer. International Publishing 2023;121–150. doi: 10.3390/diagnostics13030478</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Титов ВН, Щёкотова АП. Олеиновые, пальмитиновые триглицериды, липопротеины очень низкой плотности. Атеросклероз, атероматоз артерий и патогенез ишемической болезни сердца. Пермский медицинский журнал 2019; 36(1):102–117. doi: 10.17816/pmj361102%117</mixed-citation><mixed-citation xml:lang="en">Titov VN, Schekotova AP. Oleic, palmitic triglycerides, very low density lipoproteins. atherosclerosis, arterial atheromatosis and ischemic heart disease pathogenesis. Permskiy meditsinskiy zhurnal 2019; 36(1):102–117. (In Russ.) doi: 10.17816/pmj361102%117</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cynn E, Li DY, O’Reilly ME et al. Human Macrophage Long Intergenic Noncoding RNA, SIMALR, Suppresses Inflammatory Macrophage Apoptosis via NTN1 (Netrin-1). Arteriosclerosis, Thrombosis, and Vascular Biology 2023;43(2):286–299. doi: 10.1161/ATVBAHA.122.318353</mixed-citation><mixed-citation xml:lang="en">Cynn E, Li DY, O’Reilly ME et al. Human Macrophage Long Intergenic Noncoding RNA, SIMALR, Suppresses Inflammatory Macrophage Apoptosis via NTN1 (Netrin-1). Arteriosclerosis, Thrombosis, and Vascular Biology 2023;43(2):286–299. doi: 10.1161/ATVBAHA.122.318353</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ties D, van der Ende YM, Pundziute G et al. Pre-screening to guide coronary artery calcium scoring for early identification of high-risk individuals in the general population. European Heart Journal-Cardiovascular Imaging 2023; 24(1):27–35. doi: 10.1093/ehjci/jeac137</mixed-citation><mixed-citation xml:lang="en">Ties D, van der Ende YM, Pundziute G et al. Pre-screening to guide coronary artery calcium scoring for early identification of high-risk individuals in the general population. European Heart Journal-Cardiovascular Imaging 2023; 24(1):27–35. doi: 10.1093/ehjci/jeac137</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kim DW, Rhee H. Interpretation of Estimated Glomerular Filtration Rate. The Korean Journal of Medicine 2023; 98(1):45–51. doi: 10.3904/kjm.2023.98.1.45</mixed-citation><mixed-citation xml:lang="en">Kim DW, Rhee H. Interpretation of Estimated Glomerular Filtration Rate. The Korean Journal of Medicine 2023; 98(1):45–51. doi: 10.3904/kjm.2023.98.1.45</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Исайкина МА, Исаев ГО, Пятигорец ЕС и др. Язвенный колит и сердечно-сосудистые заболевания. Клинический пример. Системные гипертензии 2022;19(4):53–57. doi: 10.38109/2075-082X-2022-4-53-57</mixed-citation><mixed-citation xml:lang="en">Isaikina MA, Isaev GO, Pyatigorets ES et al. Ulcerative colitis and cardiovascular disease. Case report. Systemnye gipertenzii 2022;19(4):53–57. (In Russ). doi: 10.38109/2075-082X-2022-4-53-57. (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Агиенко АС, Строкольская ИЛ, Херасков ВЮ, Артамонова ГВ. Эпидемиология факторов риска болезней системы кровообращения и обращаемость населения за медицинской помощью. Комплексные проблемы сердечно-сосудистых заболеваний 2022;11(4):79–89. doi: 10.17802/2306-1278-202211-4-79-89</mixed-citation><mixed-citation xml:lang="en">Agienko AS, Strokolskaya IL, Heraskov VYu, Artamonova GV. Epidemiology of cardiovascular risk factors and the medical care appealability. Kompleksnye problemy serdechno-sosudistykh zabolevaniy 2022;11(4):79–89. (In Russ.) doi: 10.17802/2306-12782022-11-4-79-89</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Симбирцев АС, Тотолян АА. Цитокины в лабораторной диагностике. Инфекционные болезни: Новости. мнения. обучение 2015;2(11):82–98</mixed-citation><mixed-citation xml:lang="en">Simbirtsev AS, Totolyan AA. Cytokines in laboratory diagnostics. Infectious diseases: Novosti, mneniya, obuchenie 2015;2(11):82–98. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Коротаева АА, Самойлова ЕВ, Миндзаев ДР и др. Провоспалительные цитокины при хронической сердечной недостаточности: состояние проблемы. Терапевтический архив 2021;93(11):1389–1394. doi: 10.26442/00403660.2021.11.201170</mixed-citation><mixed-citation xml:lang="en">Korotaeva AA, Samoilova EV, Mindzaev DR et al. Pro-inflammatory cytokines in chronic cardiac failure: state of problem. Terapevticheskiy Arkhiv 2021; 93(11):1389–1394. (In Russ) doi:10.26442/00403660.2021.11.201170</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Фролов АВ, Барбараш ОЛ. Клиническая и прогностическая ценность определения концентрации в крови интерлейкина-12 у пациентов с мультифокальным атеросклерозом, подвергшихся каротидной эндартерэктомии. Атеросклероз 2014;10(2):31–36</mixed-citation><mixed-citation xml:lang="en">Frolov AV, Barbarash OL. Clinical and prognostic importance of assessment of interleukin-12 blood concentration in patients with multifocal atherosclerosis after carotid endarterectomy. Ateroskleroz 2014; 10(2):31–36. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Каргальцева НМ, Кочеровец ВИ, Миронов АЮ и др. Маркёры воспаления и инфекция кровотока (oбзор литературы). Клиническая лабораторная диагностика 2019;64(7):435–442. doi: 10.18821/0869-2084-2019-64-7-435-442</mixed-citation><mixed-citation xml:lang="en">Kargal`tseva NM, Kocherovets VI, Mironov AYu et al. Inflammation markers and bloodstream infection (review of literature). Klinicheskaya Laboratornaya Diagnostika 2019; 64(7): 435–442. doi: 10.18821/0869-2084-2019-64-7-435-442. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Дутова СВ, Саранчина ЮВ, Карпова МР и др. Цитокины и атеросклероз – новые направления исследований. Бюллетень сибирской медицины 2018;17:4:199–207.doi: 10.20538/16820363-2018-4-199–207</mixed-citation><mixed-citation xml:lang="en">Dutova SV, Saranchina JV, Karpova MR et al. Cytokines and atherosclerosis – new research directions. Bulleten` Sibirskoy Meditsiny 2018; 17(4):199–207. doi: 10.20538/1682-0363-2018-4-199–207. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Алфёрова ВИ, Мустафина СВ. Роль адипокинов в формировании кардиометаболических нарушений у человека. Атеросклероз 2022;18(4):388–394. doi: 10.52727/2078-256X2022-18-4-388-394</mixed-citation><mixed-citation xml:lang="en">Alferova VI, Mustafina SV. The role of adipokines in the development of cardiometabolic disorders in humans. Ateroscleroz 2022;18(4):388–394. doi: 10.52727/2078-256X-2022-18-4-388-394. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Dimosiari A, Patoulias D, Kitas GD, Dimitroulas T. Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence. Journal of Clinical Medicine 2023;1(4):1302</mixed-citation><mixed-citation xml:lang="en">Dimosiari A, Patoulias D, Kitas GD, Dimitroulas T. Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence. Journal of Clinical Medicine 2023;1(4):1302</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Biros E, Reznik JE, Moran CS. Role of inflammatory cytokines in genesis and treatment of atherosclerosis. Trends Cardiovasc Med 2022; 32(3):138–142. doi: 10.1016/j.tcm.2021.02.001</mixed-citation><mixed-citation xml:lang="en">Biros E, Reznik JE, Moran CS. Role of inflammatory cytokines in genesis and treatment of atherosclerosis. Trends Cardiovasc Med 2022; 32(3):138–142. doi: 10.1016/j.tcm.2021.02.001</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Никитин ЮП, Cимонова ГИ, Хорева МА и др. Роль дисфункции эндотелия в патогенезе атеросклероза. Атеросклероз 2011;7(1):60–69</mixed-citation><mixed-citation xml:lang="en">Nikitin YuP, Simonova GI, Khoreva MA et al. Role of endothelial dysfunction in pathogenesis of atherosclerosis. Ateroscleroz 2011; 7(1):60–69. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Maqsood M, Sharif S, Naz S et al. Expression of proinflammatory cytokines (IL-6 &amp; IL-18) exacerbate the risk of diabetic nephropathy in the Pakistani population. Molecular Biology Reports 2023:1–9. doi: 10.1007/s11033-023-08249-z</mixed-citation><mixed-citation xml:lang="en">Maqsood M, Sharif S, Naz S et al. Expression of proinflammatory cytokines (IL-6 &amp; IL-18) exacerbate the risk of diabetic nephropathy in the Pakistani population. Molecular Biology Reports 2023:1–9. doi: 10.1007/s11033-023-08249-z</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974; 304(7880):556–560. doi: 10.1016/s0140-6736(74)91880-7</mixed-citation><mixed-citation xml:lang="en">Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974; 304(7880):556–560. doi: 10.1016/s0140-6736(74)91880-7</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Savin VJ, Sharma R, Sharma M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334(14):878–883. doi: 10.1056/nejm199604043341402</mixed-citation><mixed-citation xml:lang="en">Savin VJ, Sharma R, Sharma M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334(14):878–883. doi: 10.1056/nejm199604043341402</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Чеботарева НВ, Виноградов А, Гиндис АА и др. Нарушение баланса провоспалительных цитокинов и Т-регуляторных клеток у больных хроническим гломерулонефритом. Терапевтический архив 2020; 92(6):46–52. doi: 10. 26442/00403660.2020.06.000671</mixed-citation><mixed-citation xml:lang="en">Chebotareva NV, Vinogradov AA, Gindis AA et al. The balance of proinflammatory cytokines and Treg cells in chronic glomerulonephritis. Terapevticheskiy Arkhiv 2020;92(6):46–52. (In Russ.) doi: 10.26442/00403660.2020.06.000671</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Misra N, Bayry J, Lacroix-Desmazes S et al. Cutting edge: human CD4+/CD25+ T cells restrain the maturation and antigenpresenting function of dendritic cells. J Immunol 2004; 172(8):4676– 4680. doi: 10.4049/jimmunol.172.8.4676</mixed-citation><mixed-citation xml:lang="en">Misra N, Bayry J, Lacroix-Desmazes S et al. Cutting edge: human CD4+/CD25+ T cells restrain the maturation and antigenpresenting function of dendritic cells. J Immunol 2004; 172(8):4676– 4680. doi: 10.4049/jimmunol.172.8.4676</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Гуссаова СС, Бобкова ИН, Яшков ЮИ и др. Влияние хирургической коррекции массы тела на альбуминурию и нефринурию у больных с морбидным ожирением. Клиническая фармакология и терапия 2022;31(1):62–68</mixed-citation><mixed-citation xml:lang="en">Gussaova SS, Bobkova IN, Yashkov YuI et al. The effect of surgical weight correction on albuminuria and nephrinuria in patients with morbid obesity. Klinicheskaya farmakologiya i terapiya 2022; 31(1):62–68. (In Russ.) doi: 10.32756/0869-5490-2022-1-62-68</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Shimano S, Ohkawa R, Nambu M et al. Marked Changes in Serum Amyloid A Distribution and High-Density Lipoprotein Structure during Acute Inflammation. Biomed Res Int 2021;9241259. doi: 10.1155/2021/9241259</mixed-citation><mixed-citation xml:lang="en">Shimano S, Ohkawa R, Nambu M et al. Marked Changes in Serum Amyloid A Distribution and High-Density Lipoprotein Structure during Acute Inflammation. Biomed Res Int 2021;9241259. doi: 10.1155/2021/9241259</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kuchta A, Ćwiklińska A, Czaplińska M et al. Plasma Levels of Preβ1-HDL Are Significantly Elevated in Non-Dialyzed Patients with Advanced Stages of Chronic Kidney Disease. Int J Mol Sci 2019 Mar 9; 20(5):1202. doi: 10.3390/ijms20051202</mixed-citation><mixed-citation xml:lang="en">Kuchta A, Ćwiklińska A, Czaplińska M et al. Plasma Levels of Preβ1-HDL Are Significantly Elevated in Non-Dialyzed Patients with Advanced Stages of Chronic Kidney Disease. Int J Mol Sci 2019 Mar 9; 20(5):1202. doi: 10.3390/ijms20051202</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
